Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Cytokine and chemokine antibodies neutralize soluble mediators or block their receptors in immunology research. Adalimumab, infliximab and golimumab bind tumor necrosis factor alpha (TNF-α), and tocilizumab blocks the interleukin-6 (IL-6) receptor. Secukinumab and ixekizumab neutralize IL-17A, while ustekinumab, guselkumab and risankizumab act on the IL-12 and IL-23 axis. Dupilumab binds IL-4 receptor alpha, tralokinumab and lebrikizumab neutralize IL-13, and mepolizumab and benralizumab act on the IL-5 pathway. Further antibodies target IL-1β, thymic stromal lymphopoietin (TSLP) and chemokine receptors such as CCR4, which mogamulizumab binds.
Solrikitug is a human IgG1 κ monoclonal antibody targeting the cytokine receptor-like factor 2 (CRLF2). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.
Vopikitug is a human monoclonal antibody of the IgG1-kappa isotype, specifically targeting the interleukin-2 receptor alpha subunit (IL-2RA), also known as TAC, p55, or CD25. This antibody exhibits antineoplastic activity, making it relevant for research in cancer immunotherapy and the modulation of immune responses.
Synonyms: ALX-0061
Vobarilizumab (ALX-0061) is a humanized bispecific monoclonal antibody that targets both the interleukin-6 receptor (IL-6R) and human serum albumin (ALB) with a dissociation constant (Kd) of 0.19 pM. This antibody features distinct domains: one that binds to IL-6R and another that binds to human serum albumin. The dual specificity of Vobarilizumab allows for enhanced targeting and retention in the human body, making it a valuable tool in the study of inflammatory autoimmune conditions, including rheumatoid arthritis. This antibody's unique configuration and high affinity make it ideal for research applications focused on the pathogenesis and treatment strategies of such diseases.
APX-007 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the IL-6 receptor alpha (IL-6Ra/CD126). This antibody is comprised of a human IgG1 type heavy chain and a human kappa (huκ) type light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.
Synonyms: REGN-668; SAR-231893
Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα). By inhibiting signaling pathways of both interleukin-4 (IL-4) and interleukin-13 (IL-13), this antibody has demonstrated significant efficacy in ameliorating the symptoms of moderate-to-severe atopic dermatitis. This specificity makes it a valuable tool for research into the pathophysiology and treatment of allergic and inflammatory diseases.
The Anti-TNFSF2 / TNFa (ESBA 105) antibody specifically targets Tumor Necrosis Factor (TNF), a critical cytokine involved in systemic inflammation and the acute phase response. This antibody is characterized by its efficient intraocular penetration, reaching both the anterior and posterior regions of the eye, making it particularly useful in research studies focused on ocular diseases and inflammatory responses within the eye.
Synonyms: AVTX-002; AEVI 002; SAR 252067
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody designed to target LIGHT, a cytokine related to tumor necrosis factor (TNF) identified as TNFSF14. This cytokine is critically involved in the pathogenesis of acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS), particularly noted in COVID-19 cases. The therapeutic potential of Quisovalimab extends to its application in research focused on COVID-19-induced ARDS and related inflammatory conditions, providing a valuable tool for studies aimed at understanding and mitigating cytokine-mediated diseases.
Synonyms: MEDI-545; MDX 1103
Sifalimumab (MEDI-545) is a monoclonal antibody that targets and neutralizes multiple subtypes of interferon-alpha (IFNα), a key cytokine involved in the pathogenesis of autoimmune disorders. By binding to IFNα, Sifalimumab effectively suppresses abnormal immune responses. This antibody is particularly relevant for research into systemic lupus erythematosus (SLE), providing a valuable tool for investigating the role of IFNα in SLE pathophysiology and for exploring potential therapeutic interventions.
Synonyms: PRO 140
Leronlimab (PRO 140) is a humanized IgG4 monoclonal antibody targeting CCR5, a critical receptor involved in the entry of HIV-1 into cells and in the mediation of inflammatory processes. This antibody effectively inhibits HIV-1 viral entry and has demonstrated potential in reducing lung metastasis in mouse tumor models. Leronlimab is applicable for research in various fields including HIV, nonalcoholic steatohepatitis (NASH), and cancer, providing a versatile tool for investigating the role of CCR5 in disease progression and therapy.
Synonyms: BCD-089
Levilimab (BCD-089) is a fully humanized monoclonal antibody that targets the interleukin-6 receptor (IL-6R), playing a crucial role in the modulation of inflammatory responses. This antibody is specifically designed for the study of inflammatory diseases, including rheumatoid arthritis, where IL-6R-mediated signaling is implicated in disease pathology and progression. Levilimab provides a valuable tool for researchers investigating the therapeutic potential of IL-6R inhibition in inflammation and autoimmune disorders.
Falbikitug is a humanized IgG1-kappa monoclonal antibody targeting leukemia inhibitory factor (LIF). Classified as an antineoplastic agent, Falbikitug is designed for therapeutic applications in oncology, specifically targeting and neutralizing LIF to inhibit tumor growth and progression. This antibody may be utilized in research studies to explore the role of LIF in cancer biology and to assess its potential as a therapeutic target in various malignancies.
Synonyms: MAK 195F
Afelimomab (MAK 195F) is a monoclonal antibody fragment, specifically an F(ab')2 fragment, targeting tumor necrosis factor (TNF). This antibody fragment is utilized primarily in the study of sepsis, offering a valuable tool for researchers investigating the pathophysiology and potential therapeutic interventions for this condition.
Synonyms: BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody
Ulocuplumab, also known as BMS-936564 or MDX1338, is a fully human IgG4 monoclonal antibody targeting CXCR4. This antibody plays a critical role in modulating tumor microenvironment interactions by inducing apoptosis and inhibiting CXCL12-mediated activation and migration of CXCR4 in chronic lymphocytic leukemia (CLL) cells. Demonstrating significant antitumor efficacy, Ulocuplumab has shown activity against established tumors in various xenograft models, including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma. This antibody is pivotal for research focused on the molecular pathways of cancer cell migration and survival, offering potential therapeutic insights into multiple hematologic malignancies.
Roconkibart is a human IgG4 κ monoclonal antibody targeting IL-17A. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for the specific detection and neutralization of IL-17A, a key cytokine involved in inflammatory processes and autoimmune disorders.
IMA-026 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-13 (IL-13). This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, and possesses a predicted molecular weight of 146.88 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.
Brivekimig is a chimeric antibody composed of five variable heavy (VH) domains, specifically designed to target TNFSF4, TNFSF2, and albumin (ALB). This unique configuration enhances its specificity and binding affinity, making it an ideal tool for research into the signaling pathways and biological effects mediated by these targets. Brivekimig is suitable for use in various experimental contexts to elucidate the roles of TNFSF4 and TNFSF2 in immune regulation and inflammatory processes.
Synonyms: Anti-Human IL17A Recombinant Antibody
Vunakizumab is a recombinant human IgGκ monoclonal antibody specifically designed to target and neutralize interleukin-17A (IL-17A). By binding to IL-17A, Vunakizumab effectively prevents its interaction with the IL-17 receptor, thereby inhibiting the pro-inflammatory pathways associated with this cytokine. This antibody is particularly useful in research focused on autoimmune disorders, including psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis, where IL-17A plays a key role in disease pathogenesis.
Nebokitug is a human monoclonal antibody of the IgG1κ isotype designed to specifically target CCL24. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.
VLST-002 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CCL5/RANTES. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.
Synonyms: GR 1501
Xeligekimab (GR 1501) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin 17A (IL-17A), a key cytokine involved in the induction and maintenance of pro-inflammatory responses. By binding to IL-17A, Xeligekimab effectively inhibits the cytokine's interaction with its receptor, thereby disrupting the pro-inflammatory cascade. This antibody is utilized in research focused on inflammatory diseases to understand the role of IL-17A in disease pathology and to evaluate potential therapeutic interventions.
Synonyms: SRF-388
Casdozokitug (SRF-388) is a monoclonal antibody of the IgG1κ subclass that specifically targets interleukin-27 (IL-27). This antibody has been developed for its potential application in modulating immune responses, given IL-27's role in inflammatory processes. Casdozokitug is suitable for use in various immunological assays to study IL-27's biological functions and its implications in immune regulation and disease pathogenesis.
Synonyms: ZTS-00521426
Cirevetmab (ZTS-00521426) is a caninized monoclonal antibody specifically designed for targeting Canis lupus familiaris TGFB1. Classified as an immunoglobulin G2-kappa, this antibody serves as an immunomodulator, influencing cellular responses and immune regulation in therapeutic applications. Cirevetmab is engineered for high specificity and efficacy in modulating the biological activity of TGFB1, making it an essential tool for research in canine immunological disorders.
Synonyms: MORAb-022
Gimsilumab (MORAb-022) is a human monoclonal antibody that targets granulocyte-macrophage colony-stimulating factor (GM-CSF). This antibody exhibits potential for use in research focused on COVID-19 and rheumatoid arthritis (RA), providing a valuable tool for investigating the role of GM-CSF in inflammation and immune response associated with these conditions.
Synonyms: RPC 4046; ABT 308; CC-93538
Cendakimab (RPC4046; ABT 308; CC-93538) is a humanized, recombinant monoclonal antibody engineered to selectively target the interleukin-13 (IL-13) cytokine. Demonstrating high affinity and potency, this antibody effectively binds to both the wild-type and variant forms of human IL-13. Cendakimab inhibits the interaction of IL-13 with its receptors, IL-13Rα1 and IL-13Rα2, exhibiting half-maximal inhibitory concentrations (IC50s) of 352 pM and 631 pM, respectively, as determined by enzyme-linked immunosorbent assay (ELISA). Furthermore, it exhibits binding affinities of 52 pM for wild-type IL-13 and 50 pM for the R110Q polymorphic variant of IL-13. The therapeutic potential of Cendakimab spans various IL-13-mediated allergic and inflammatory conditions, including asthma and eosinophilic esophagitis.
Anti-IL-9 Antibody (MH9A4) is a mouse monoclonal antibody of the IgG2b, κ subclass, specifically designed to target human interleukin-9 (IL-9). This chimeric antibody is engineered for high specificity and affinity in recognizing and binding to IL-9, a cytokine involved in various inflammatory and immune responses. For appropriate experimental controls, it is recommended to use Mouse IgG2b kappa, Isotype Control, which serves as a non-reactive isotype control to help distinguish specific from non-specific binding.
